Diversity has become ingrained as a priority in the oncology space, but industry could get stuck discussing existing barriers without formulating clear plans for taking action. FDA Oncology Center of Excellence (OCE) officials, sponsors and the American Association for Cancer Research (AACR) discuss these hurdles and potential next steps at length in a recent Clinical Cancer Research journal article.